Skip to main content
. 2016 Jun 10;291(32):16508–16518. doi: 10.1074/jbc.M116.738765

FIGURE 4.

FIGURE 4.

ESI-MS analysis of the glycosylation remodeling of rituximab using Endo-S2 D184M. A, ESI-MS (after deconvolution) of the heavy chain of the commercial rituximab; B, ESI-MS of the heavy chain of the Fucα1,6GlcNAc-rituximab (2); C and D, ESI-MS of the heavy chain and light chain of transglycosylation product 3 (SCT-rituximab), respectively; E and F, ESI-MS of the heavy chain and light chain of transglycosylation product 8 (HM-rituximab); G and H, ESI-MS of the heavy chain and light chain of transglycosylation product 6 (Hyb-rituximab); I and J, ESI-MS of the heavy chain and light chain of transglycosylation product 11 (non-fucosylated rituximab).